Steve Harr (L) and Hans Bishop
One of the most ambitious startup teams in biotech just outlined plans for a $400M IPO and a valuation of about $4B
The executive team at Sana Biotechnology has sketched out more details about the full scope of its ambitions as the new unicorn to watch …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
